Lipid nanocapsules: A new platform for nanomedicine

International Journal of Pharmaceutics

Volumn 379, Issue 2, 2009, Pages 201-209

  Huynh, N T ^a   Passirani, C ^a   Saulnier, P ^a   Benoit, J P ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

Anticancer drugs; Nanocarriers; Nanotechnology; Targeting

Indexed keywords

4 HYDROXYTAMOXIFEN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FERROCIPHENOL; GLYCOPROTEIN P; INDIUM 111; IODINE 125; LIPID NANOCAPSULE; LIPOSOME; MACROGOL; NANOCAPSULE; NONIONIC SURFACTANT; ORGANOMETALLIC COMPOUND; PACLITAXEL; PHOSPHATIDYLCHOLINE; RHENIUM 188; TECHNETIUM 99M; TENIPOSIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; COLON ADENOCARCINOMA; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG TUMOR LEVEL; GLIOMA; HUMAN; NANOEMULSION; NANOENCAPSULATION; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SURVIVAL TIME; SUSTAINED RELEASE FORMULATION; TUMOR CELL DESTRUCTION; TUMOR REGRESSION;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOCAPSULES; NANOMEDICINE;

EID: 68949214375     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.04.026     Document Type: Review

References (85)

1. Abismail B., Canselier J.P., Wilhelm A.M., Delmas H., and Gourdon C. Emulsification by ultrasound: drop size distribution and stability. Ultrason. Sonochem. 6 (1999) 75-83
2. 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 1838-1846
3. Allard E., Passirani C., and Benoit J.P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30 (2009) 2302-2318
4. Allard E., Passirani C., Garcion E., Pigeon P., Vessieres A., Jaouen G., and Benoit J.P. Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. J. Control. Release 130 (2008) 146-153
5. Allard, E., Passirani, C., Jarnet, D., Petit, S., Vessieres, A., Jaouen, G., Benoit, J.P., submitted for publication. Local delivery of ferrocifenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft. J. Pharmacol. Exp. Ther.
6. Anton N., Benoit J.P., and Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J. Control. Release 128 (2008) 185-199
7. Anton N., Gayet P., Benoit J.P., and Saulnier P. Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion. Int. J. Pharm. 344 (2007) 44-52
8. Anton N., Saulnier P., Beduneau A., and Benoit J.P. Salting-out effect induced by temperature cycling on a water/nonionic surfactant/oil system. J. Phys. Chem. B 111 (2007) 3651-3657
9. 188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 602-607
10. Beduneau A., Hindre F., Clavreul A., Leroux J.C., Saulnier P., and Benoit J.P. Brain targeting using novel lipid nanovectors. J. Control. Release 126 (2008) 44-49
11. Beduneau A., Saulnier P., Anton N., Hindre F., Passirani C., Rajerison H., Noiret N., and Benoit J.P. Pegylated nanocapsules produced by an organic solvent-free method: evaluation of their stealth properties. Pharm. Res. 23 (2006) 2190-2199
12. Beduneau A., Saulnier P., and Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 28 (2007) 4947-4967
13. Beduneau A., Saulnier P., Hindre F., Clavreul A., Leroux J.C., and Benoit J.P. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab′ fragments. Biomaterials 28 (2007) 4978-4990
14. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., and Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 2076-2080
15. Bouchemal K., Briancon S., Perrier E., and Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int. J. Pharm. 280 (2004) 241-251
16. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 (2002) 631-651
17. Caruthers S.D., Wickline S.A., and Lanza G.M. Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 18 (2007) 26-30
18. Coon J.S., Knudson W., Clodfelter K., Lu B., and Weinstein R.S. Solutol HS, 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res. 51 (1991) 897-902
19. Dulieu C., and Bazile D. Influence of lipid nanocapsules composition on their aptness to freeze-drying. Pharm. Res. 22 (2005) 285-292
20. Fenart L., Casanova A., Dehouck B., Duhem C., Slupek S., Cecchelli R., and Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 291 (1999) 1017-1022
21. Floury J., Desrumaux A., Axelos M.A.V., and Legrand J. Effect of high pressure homogenisation on methylcellulose as food emulsifier. J. Food Eng. 58 (2003) 227-238
22. Friberg S., Lapczynska I., and Gillberg G. Microemulsions containing nonionic surfactants-the importance of the pit value. J. Colloids Interface Sci. 56 (1976) 19-32
23. Friden P.M., Walus L.R., Musso G.F., Taylor M.A., Malfroy B., and Starzyk R.M. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 4771-4775
24. Garcion E., Lamprecht A., Heurtault B., Paillard A., Aubert-Pouessel A., Denizot B., Menei P., and Benoit J.P. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 5 (2006) 1710-1722
25. Ghofrani H.A., Osterloh I.H., and Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5 (2006) 689-702
26. Haley B., and Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26 (2008) 57-64
27. Hall W.A. Transferrin receptor on glioblastoma multiforme. J. Neurosurg. 74 (1991) 313-314
28. Heurtault B., Saulnier P., Pech B., Benoit J.P., and Proust J.E. Interfacial stability of lipid nanocapsules. Colloids Surf. B: Biointerfaces 30 (2003) 225-235
29. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19 (2002) 875-880
30. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. Properties of polyethylene glycol 660 12-hydroxy stearate at a triglyceride/water interface. Int. J. Pharm. 242 (2002) 167-170
31. Heurtault B., Saulnier P., Pech B., Proust J.E., and Benoit J.P. Physico-chemical stability of colloidal lipid particles. Biomaterials 24 (2003) 4283-4300
32. Heurtault, B., Saulnier, P., Pech, B., Proust, J.E., Richard, J., Benoit, J.P., 2000. Lipidic nanocapsules: preparation process and use as Drug Delivery Systems. Patent No. WO02688000.
33. Heurtault B., Saulnier P., Pech B., Venier-Julienne M.C., Proust J.E., Phan-Tan-Luu R., and Benoit J.P. The influence of lipid nanocapsule composition on their size distribution. Eur. J. Pharm. Sci. 18 (2003) 55-61
34. Hoarau D., Delmas P., David S., Roux E., and Leroux J.C. Novel long-circulating lipid nanocapsules. Pharm. Res. 21 (2004) 1783-1789
35. Jallouli Y., Paillard A., Chang J., Sevin E., and Betbeder D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int. J. Pharm. 344 (2007) 103-109
36. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., and Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 312 (1984) 162-163
37. Jestin E., Mougin-Degraef M., Faivre-Chauvet A., Remaud-Le Saec P., Hindre F., Benoit J.P., Chatal J.F., Barbet J., and Gestin J.F. Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapy. Q. J. Nucl. Med. Mol. Imaging 51 (2007) 51-60
38. Khalid M.N., Simard P., Hoarau D., Dragomir A., and Leroux J.C. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm. Res. 23 (2006) 752-758
39. Lacoeuille F., Hindre F., Moal F., Roux J., Passirani C., Couturier O., Cales P., Le Jeune J.J., Lamprecht A., and Benoit J.P. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. Int. J. Pharm. 344 (2007) 143-149
40. Lamprecht A., and Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 112 (2006) 208-213
41. Lamprecht A., Bouligand Y., and Benoit J.P. New lipid nanocapsules exhibit sustained release properties for amiodarone. J. Control. Release 84 (2002) 59-68
42. Lamprecht A., Saumet J.L., Roux J., and Benoit J.P. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. Int. J. Pharm. 278 (2004) 407-414
43. Letchford K., and Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 65 (2007) 259-269
44. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
45. Malzert-Freon A., Vrignaud S., Saulnier P., Lisowski V., Benoit J.P., and Rault S. Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent. Int. J. Pharm. 320 (2006) 157-164
46. Manconi M., Aparicio J., Vila A.O., Pendas J., Figueruelo J., and Molina F. Viscoelastic properties of concentrated dispersions in water of soy lecithin. Colloids Surf. A: Physicochem. Eng. Aspects 222 (2003) 141-145
47. Maruyama K., Takahashi N., Tagawa T., Nagaike K., and Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413 (1997) 177-180
48. Miller D.J., Henning T., and Grunbein W. Phase inversion of W/O emulsions by adding hydrophilic surfactant-a technique for making cosmetics products. Colloids Surf. A: Physicochem. Eng. Aspects 183-185 (2001) 681-688
49. Minkov I., Ivanova T., Panaiotov I., Proust J., and Saulnier P. Reorganization of lipid nanocapsules at air-water interface. Part 2. Properties of the formed surface film. Colloids Surf. B: Biointerfaces 44 (2005) 197-203
50. Modok S., Mellor H.R., and Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 6 (2006) 350-354
51. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
52. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42 (2003) 463-478
53. Morales D., Gutierrez J.M., Garcia-Celma M.J., and Solans Y.C. A study of the relation between bicontinuous microemulsions and oil/water nano-emulsion formation. Langmuir 19 (2003) 7196-7200
54. Morille M., Passirani C., Letrou-Bonneval E., Benoit J.P., and Pitard B. Galactosylated DNA lipid nanocapsules for an efficient hepatocyte targeting. Int. J. Pharm. 379 (2009) 293-300
55. Morille M., Passirani C., Vonarbourg A., Clavreul A., and Benoit J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29 (2008) 3477-3496
56. Mosqueira V.C., Legrand P., Gulik A., Bourdon O., Gref R., Labarre D., and Barratt G. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22 (2001) 2967-2979
57. Mosqueira V.C., Legrand P., Morgat J.L., Vert M., Mysiakine E., Gref R., Devissaguet J.P., and Barratt G. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm. Res. 18 (2001) 1411-1419
58. Naccarelli G.V., Rinkenberger R.L., Dougherty A.H., and Giebel R.A. Amiodarone: pharmacology and antiarrhythmic and adverse effects. Pharmacotherapy 5 (1985) 298-313
59. Ohgaki H., and Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 109 (2005) 93-108
60. Oostendorp R.L., Beijnen J.H., and Schellens J.H. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat. Rev. 35 (2009) 137-147
61. Osterloh I.H., and Riley A. Clinical update on sildenafil citrate. Br. J. Clin. Pharmacol. 53 (2002) 219-223
62. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 (2005) 3-14
63. Pardridge W.M., Buciak J.L., and Friden P.M. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259 (1991) 66-70
64. Passirani C., and Benoit J.P. Complement activation by injectable colloidal drug carriers. Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (2005), CRC Press, Inc., Boca Raton pp. 187-230
65. Peltier S., Oger J.M., Lagarce F., Couet W., and Benoit J.P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23 (2006) 1243-1250
66. Pereira de Oliveira M., Garcion E., Venisse N., Benoit J.P., Couet W., and Olivier J.C. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. Pharm. Res. 22 (2005) 1898-1905
67. Saulnier P., Anton N., Heurtault B., and Benoit J.-P. Liquid crystals and emulsions in the formulation of drug carriers. Comptes Rendus Chimie 11 (2008) 221-228
68. Sawyer A.J., Piepmeier J.M., and Saltzman W.M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med. 79 (2006) 141-152
69. Shah J.C., Chen J.R., and Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm. Res. 6 (1989) 408-412
70. Shinoda K., and Saito H. The stability of O/W type emulsions as functions of temperature and the HLB of emulsifiers: the emulsification by PIT-method. J. Colloids Interface Sci. 30 (1969) 258-263
71. Solans C., Izquierdo P., Nolla J., Azemar N., and Garcia-Celma M.J. Nano-emulsions. Curr. Opin. Colloids Interface Sci. 10 (2005) 102-110
72. Sparreboom A., and Nooter K. Does P-glycoprotein play a role in anticancer drug pharmacokinetics?. Drug Resist. Updat. 3 (2000) 357-363
73. Sparreboom A., van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K., Borst P., Nooijen W.J., Beijnen J.H., and van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2031-2035
74. Steiniger S.C., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., and Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer. 109 (2004) 759-767
75. Tadros T., Izquierdo P., Esquena J., and Solans C. Formation and stability of nano-emulsions. Adv. Colloids Interface Sci. 108-109 (2004) 303-318
76. Undevia S.D., Gomez-Abuin G., and Ratain M.J. Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 5 (2005) 447-458
77. Vogelbaum M.A. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J. Neuro-Oncol. 73 (2005) 57-69
78. Vonarbourg A., Saulnier P., Passirani C., and Benoit J.P. Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface. Electrophoresis 26 (2005) 2066-2075
79. Vonarbourg A., Passirani C., Saulnier P., and Benoit J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27 (2006) 4356-4373
80. Vonarbourg A., Passirani C., Saulnier P., Simard P., Leroux J.C., and Benoit J.P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 78 (2006) 620-628
81. Vonarbourg A., Passirani C., Desigaux L., Allard E., Saulnier P., Lambert O., Benoit J.P., and Pitard B. The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials. 30 (2009) 3197-3204
82. Wawrezinieck A., Pean J.-M., Wuthrich P., and Benoit J.-P. Oral bioavailability and drug/carrier particulate systems. Medicine/Sciences 24 (2008) 659-664
83. Wehrlé P. Chapitre 3: liposomes. Pharmacie galénique: formulation et technologie pharmaceutique (2007), Maloine pp. 241-250
84. Winsor P. Solvent Properties of Amphiphilic Compounds (1954), Butterworth Londres
85. ® liposomal doxorubicin HCl). Human Exp. Toxicol. 15 (1996) 751-785